title: Neoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancer.
abstract: Three main xenobiotic efflux pumps have been implicated in modulating breast cancer chemotherapy responses. These are P-glycoprotein (Pgp), Multidrug Resistance-associated Protein 1 (MRP1), and Breast Cancer Resistance Protein (BCRP). We investigated expression of these proteins in breast cancers before and after neoadjuvant chemotherapy (NAC) to determine whether their levels define response to NAC or subsequent survival. Formalin-fixed paraffin-embedded tissues were collected representing matched pairs of core biopsy (pre-NAC) and surgical specimen (post-NAC) from 45 patients with invasive ductal carcinomas. NAC regimes were anthracyclines +/- taxanes. Immunohistochemistry was performed for Pgp, MRP1 and BCRP and expression was quantified objectively using computer-aided scoring. Pgp and MRP1 were significantly up-regulated after exposure to NAC (Wilcoxon signed-rank p = 0.0024 and p<0.0001), while BCRP showed more variation in response to NAC, with frequent up- (59% of cases) and down-regulation (41%) contributing to a lack of significant difference overall. Pre-NAC expression of all markers, and post-NAC expression of Pgp and MRP1 did not correlate with NAC response or with disease-free survival (DFS). Post-NAC expression of BCRP did not correlate with NAC response, but correlated significantly with DFS (Log rank p = 0.007), with longer DFS in patients with low post-NAC BCRP expression. In multivariate Cox regression analyses, post-NAC BCRP expression levels proved to predict DFS independently of standard prognostic factors, with high expression associated with a hazard ratio of 4.04 (95% confidence interval 1.3-12.2; p = 0.013). We conclude that NAC-induced expression levels of BCRP predict survival after NAC for breast cancer, while Pgp and MRP1 expression have little predictive value.
authors: Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom.
authors: Baek
authors: B
authors: Kim
authors: Hiba
authors: H
authors: Fatayer
authors: Andrew M
authors: AM
authors: Hanby
authors: Kieran
authors: K
authors: Horgan
authors: Sarah L
authors: SL
authors: Perry
authors: Elizabeth M A
authors: EM
authors: Valleley
authors: Eldo T
authors: ET
authors: Verghese
authors: Bethany J
authors: BJ
authors: Williams
authors: James L
authors: JL
authors: Thorne
authors: Thomas A
authors: TA
authors: Hughes
mesh_terms: D018528:ATP-Binding Cassette Transporters / Q000378:metabolism*; D000328:Adult; D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy*; D015331:Cohort Studies; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D015854:Up-Regulation
chemical_list: D018528:ATP-Binding Cassette Transporters
references: Int J Biochem Mol Biol. 2012;3(1):1-27
references: 22509477
references: Mol Pharmacol. 2006 Apr;69(4):1499-505
references: 16434618
references: Diagn Pathol. 2011 Sep 27;6:90
references: 21943250
references: Oncogene. 2003 Oct 20;22(47):7340-58
references: 14576842
references: Expert Opin Pharmacother. 2005 Aug;6(9):1477-91
references: 16086636
references: Ann Surg Oncol. 2012 May;19(5):1508-16
references: 22193884
references: Cancer Sci. 2007 Feb;98(2):231-9
references: 17297656
references: Curr Drug Targets. 2011 May;12(5):621-30
references: 21039338
references: Endocr Relat Cancer. 2003 Mar;10(1):43-73
references: 12653670
references: Clin Cancer Res. 2003 Feb;9(2):827-36
references: 12576456
references: Eur J Surg Oncol. 2011 Feb;37(2):155-61
references: 21111561
references: Proc Natl Acad Sci U S A. 1992 Jul 1;89(13):5824-8
references: 1352877
references: Br J Surg. 2007 Oct;94(10):1189-200
references: 17701939
references: Clin Cancer Res. 1998 Jun;4(6):1533-42
references: 9626474
references: Breast Cancer. 1997 Dec 25;4(4):259-263
references: 11091611
references: Breast Cancer Res Treat. 2012 May;133(1):49-59
references: 21796367
references: Semin Oncol. 2005 Dec;32(6 Suppl 7):S9-15
references: 16360717
references: Clin Cancer Res. 1996 Jul;2(7):1231-7
references: 9816292
references: Br J Cancer. 2012 Nov 20;107(11):1892-900
references: 23079573
references: PLoS One. 2012;7(9):e45865
references: 23049880
references: Clin Cancer Res. 1998 Feb;4(2):389-98
references: 9516927
references: Int J Cancer. 2004 Nov 1;112(2):286-94
references: 15352042
references: Chin J Cancer. 2012 Feb;31(2):73-99
references: 22098950
references: FEBS Lett. 2008 Jul 23;582(17):2595-600
references: 18588889
references: Breast. 2012 Oct;21(5):669-77
references: 22863284
references: Breast Cancer Res Treat. 2003 Sep;81(2):149-57
references: 14572157
references: Nat Rev Cancer. 2010 Feb;10(2):147-56
references: 20075923
references: Oncologist. 2003;8(5):411-24
references: 14530494
references: World J Surg Oncol. 2005 Sep 14;3:61
references: 16164742
references: J Clin Oncol. 2010 May 1;28(13):2198-206
references: 20368555
references: Breast J. 2010 May-Jun;16(3):252-63
references: 20408828
references: Br J Cancer. 2006 Feb 27;94(4):473-80
references: 16434992
references: Drug Resist Updat. 2012 Feb-Apr;15(1-2):50-61
references: 22464282